Degron Therapeutics
PrivateLast Round
Series A
Extension
May 14, 2026
Total Funding Raised
$132M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Degron Therapeutics is a biotechnology company developing a new class of small-molecule medicines that target previously undruggable targets using its proprietary molecular glue-based targeted protein degradation drug discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Degron Therapeutics Comparables
Compare Degron Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Proxygen | 92% | |
| SEED Therapeutics | 90% | |
| Neomorph | 89% | |
Degron Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | May 14, 2026 | ||||
| Strategic | May 23, 2024 | ||||
| Series A | Jun 9, 2022 | ||||
| Seed | Apr 1, 2021 |
Key People
Founding team and executive leadership
Degron Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DYEE Capital | Series A |
| Fengchuan Capital | Series A |
| Longmen Capital | Series A |
| Co-Win Ventures | Series A, Seed |
| YuanBio Venture Capital | Series A, Seed |
| Baidu Ventures | Series A |
| GF Xinde Investment Management | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Grew 23% QoQ, from 22 to 27 employees.
- May 14, 2026
$40M round led by Lapam Capital.
Degron Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Degron Therapeutics's valuation, stock price, and market status.